Back to top
more

Argenx (ARGX)

(Delayed Data from NSDQ)

$877.72 USD

877.72
351,969

-14.54 (-1.63%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $877.31 -0.41 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

KROS or ARGX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

KROS vs. ARGX: Which Stock Is the Better Value Option?

Zacks Equity Research

KROS vs. ARGX: Which Stock Is the Better Value Option?

by Zacks Equity Research

KROS vs. ARGX: Which Stock Is the Better Value Option?

Sundeep Ganoria headshot

Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis

by Sundeep Ganoria

AMGN gains momentum as Uplizna wins FDA approval for generalized myasthenia gravis, adding a twice-yearly dosing option in a crowded autoimmune market.

Zacks Equity Research

KROS vs. ARGX: Which Stock Is the Better Value Option?

by Zacks Equity Research

KROS vs. ARGX: Which Stock Is the Better Value Option?

Zacks Equity Research

Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View

by Zacks Equity Research

HALO posts strong third-quarter results with earnings and revenues topping estimates and raises 2025 guidance on robust royalty growth.

Zacks Equity Research

INCY or ARGX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

INCY vs. ARGX: Which Stock Is the Better Value Option?

Zacks Equity Research

INCY vs. ARGX: Which Stock Is the Better Value Option?

by Zacks Equity Research

INCY vs. ARGX: Which Stock Is the Better Value Option?

Zacks Equity Research

AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease

by Zacks Equity Research

ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.

Zacks Equity Research

Are Medical Stocks Lagging Argenx (ARGX) This Year?

by Zacks Equity Research

Here is how argenex SE (ARGX) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

Zacks Equity Research

KMDA or ARGX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

KMDA vs. ARGX: Which Stock Is the Better Value Option?